2026-04-13T07:19:44Zhttps://recercat.cat/oai/requestoai:recercat.cat:11351/134672025-10-24T10:58:12Zcom_2072_378068com_2072_378040col_2072_378090
RECERCAT
author
Amigó, Núria
author
Julve, Josep
author
Hernández, Marta
author
Ribalta, Josep
author
Guardiola, Montse
author
López-Lifante, Víctor-Miguel
author
Herrero-Alonso, Cecilia
author
Arteaga Pillasagua, Ingrid
author
Ortega, Emilio
author
Martínez-Micaelo, Neus
author
Franch-Nadal, Josep
author
Mauricio, Didac
author
Castelblanco, Esmeralda
author
Alonso Pedrol, Nuria
author
Torán-Monserrat, Pere
2025-10-24T10:58:12Z
2025-10-24T10:58:12Z
2025-08-04T07:07:27Z2025-08-04T07:07:27Z2025-02-21
http://hdl.handle.net/11351/13467
Biomarker; Cardiovascular events; Diabetes mellitus; Glycoproteins; Lipoproteins; Nuclear magnetic resonance spectroscopy; Type 2 diabetesBiomarcador; Esdeveniments cardiovasculars; Diabetis mellitus; glicoproteïnes; LipoproteïnesBiomarcador; Eventos cardiovasculares; Diabetes mellitus; Glicoproteínas; LipoproteínasTraditional risk factors cannot accurately predict cardiovascular events (CVE) in type 2 diabetes (T2D). The LIPOCAT study aimed to prospectively evaluate the clinical utility of advanced lipoprotein characteristics and glycoproteins to predict future cardiovascular events (CVE) in a large cohort of subjects with type 2 diabetes mellitus (T2D).
From four different Spanish prospective cohorts, a total of 933 T2D subjects were selected to form the LIPOCAT study. Advanced 1H-Nuclear Magnetic Resonance (1H-NMR) analysis included lipoprotein (Liposcale®) and glycoprotein (Glycoscale) profiling. Random forest classification models and Area Under the Receiver Operating Characteristics (AUROC) analysis were used to assess the differential contribution of advanced variables in predicting CVE. Validation was performed using an external cohort.
Out of 933 T2D subjects, 104 reported a CVE during follow-up. Analysis of Liposcale®/Glycoscale uncovered elevations in the circulating VLDL-cholesterol(C), remnant IDL-triglycerides (TG) and LDL-TG in subjects with CVE, along with glycoproteins (Glyc) A and B. Moreover, the incorporation of advanced Liposcale® variables to a base model constructed with traditional risk factors significantly improved the prediction of CVE, as evidenced by 1.5-fold increase in the C statistic (AUROC), reaching AUROC values of 0.756. In the independent validation cohort, similar improvements in AUROC values were observed by adding the advanced variables to the traditional models.
Advanced 1H-NMR analysis revealed previously hidden lipoprotein and glycoprotein characteristics associated with CVE in T2D subjects.This work was supported by the Ministerio de Sanidad y Consumo and Instituto de Salud Carlos III through grant PI15/0625 (awarded to DM and EC), co-funded by the FEDER program “Una manera de hacer Europa.” Additional support was provided by Laboratorios Rubió S.A. through an unrestricted grant (LIPOCATV1FEB2018) for 1H-NMR characterization.
Attribution-NonCommercial 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ info:eu-repo/semantics/openAccess
Diabetis no-insulinodependent
Lipoproteïnes
Glicoproteïnes
DISEASES::Nutritional and Metabolic Diseases::Metabolic Diseases::Glucose Metabolism Disorders::Diabetes Mellitus::Diabetes Mellitus, Type 2
Other subheadings::Other subheadings::Other subheadings::/blood
DISEASES::Cardiovascular Diseases
Other subheadings::Other subheadings::/diagnosis
CHEMICALS AND DRUGS::Lipids::Lipoproteins
Other subheadings::Other subheadings::/analysis
CHEMICALS AND DRUGS::Carbohydrates::Glycoconjugates::Glycoproteins
ENFERMEDADES::enfermedades nutricionales y metabólicas::enfermedades metabólicas::trastornos del metabolismo de la glucosa::diabetes mellitus::diabetes mellitus tipo II
Otros calificadores::Otros calificadores::Otros calificadores::/sangre
ENFERMEDADES::enfermedades cardiovasculares
Otros calificadores::Otros calificadores::/diagnóstico
COMPUESTOS QUÍMICOS Y DROGAS::lípidos::lipoproteínas
Otros calificadores::Otros calificadores::/análisis
COMPUESTOS QUÍMICOS Y DROGAS::hidratos de carbono::glicoconjugados::glicoproteínas
Advanced serum lipoprotein and glycoprotein profiling for cardiovascular event prediction in type 2 diabetes mellitus: the LIPOCAT study
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion